Surgery Partners, Inc. (SGRY) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 22 analysts13.7% Below Target
SGRY trades 13.7% below Wall Street's consensus target of $19.33.
Current Price$17.00
Average Target$19.33
Target
Current
Low$17.00
Median$20.00
High$21.00
Analyst Target Range
Forward P/E39.6x
(Growth Premium)
PEG Ratio—
Implied Growth+172.4%
(High Growth)
Analyst Spread20.7%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes SGRY achieves its forward estimates and maintains a stable P/E multiple of 39.6x. This scenario reflects the blended consensus of 22 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
SGRY Price Target Analysis
Updated July 7, 2026As of July 7, 2026, Surgery Partners, Inc. (SGRY) has a Wall Street consensus price target of $19.33, based on estimates from 22 covering analysts. With the stock currently trading at $17.00, this represents a potential upside of +13.7%. The company has a market capitalization of $2.22B.
Analyst price targets range from a low of $17.00 to a high of $21.00, representing a 21% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SGRY trades at a trailing P/E of -27.9x and forward P/E of 39.6x. Analysts expect EPS to grow +172.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+17.1%
Industry Consensus
Avg Forward P/E
28.7x
(Growth Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 USPHU.S. Physical Therapy, Inc. | $1.1B | $73.38 | $96.00 | +30.8% | Buy | 26.2x | 13 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.51 | $17.75 | +7.5% | Hold | 13.5x | 14 |
 AMSFAMERISAFE, Inc. | $651M | $34.65 | $44.50 | +28.4% | Buy | 16.5x | 6 |
 NHCNational HealthCare Corporation | $3.4B | $217.43 | — | — | — | 27.3x | — |
 ADUSAddus HomeCare Corporation | $2.0B | $105.73 | $122.00 | +15.4% | Buy | 15.1x | 16 |
 ALHCAlignment Healthcare, Inc. | $5.0B | $24.56 | $24.33 | -0.9% | Buy | 128.9x | 16 |
 UHSUniversal Health Services, Inc. | $9.9B | $158.05 | $216.00 | +36.7% | Hold | 6.7x | 43 |
 HCAHCA Healthcare, Inc. | $92.5B | $417.07 | $504.73 | +21.0% | Buy | 13.8x | 46 |
 THCTenet Healthcare Corporation | $16.8B | $191.20 | $259.50 | +35.7% | Buy | 10.7x | 32 |
 CYHCommunity Health Systems, Inc. | $519M | $3.68 | $2.93 | -20.4% | Hold | — | 37 |
SGRY — Frequently Asked Questions
Quick answers to the most common questions about buying SGRY stock.
What is the SGRY stock price target for 2026?
Surgery Partners, Inc. (SGRY) has a consensus 12-month price target of $19.33, implying 13.7% upside from $17. The 22 analysts covering SGRY see moderate appreciation potential.
Is SGRY a buy, sell, or hold?
SGRY has a consensus rating of "Buy" based on 22 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $19.33 implies 13.7% upside from current levels.
Is SGRY stock overvalued or undervalued?
At a forward P/E of 39.627x, SGRY trades at a premium valuation. The consensus price target of $19.33 (13.7% upside) suggests analysts still see growth justifying the multiple.
How high can SGRY stock go?
The most bullish Wall Street analyst has a price target of $21 for SGRY, while the most conservative target is $17. The consensus of $19.33 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SGRY stock?
SGRY is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 8 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SGRY stock forecast?
The 12-month SGRY stock forecast based on 22 Wall Street analysts shows a consensus price target of $19.33, with estimates ranging from $17 (bear case) to $21 (bull case). The median consensus rating is "Buy".
What is SGRY's forward P/E ratio?
SGRY trades at a forward P/E ratio of 39.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SGRY stock?
Wall Street analysts are optimistic on SGRY, with a "Buy" consensus rating and $19.33 price target (13.7% upside). 14 of 22 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SGRY price targets vary so much?
SGRY analyst price targets range from $17 to $21, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19.33 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare